U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com

Last Updated: 03.07.2025 02:27

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com

June 9, 2025 3:11 pm ET

RAHWAY, N.J.--(BUSINESS WIRE)--

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has ap… [+11553 chars]

In 2019, We Discovered a Fungus That Metabolizes Gold — Some Already Want to Use These Organisms as the Key to Mining in Space - Indian Defence Review